ALSUntangled 38: L-serine.
Publication
, Journal Article
ALSUntangled Group
Published in: Amyotroph Lateral Scler Frontotemporal Degener
February 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Amyotroph Lateral Scler Frontotemporal Degener
DOI
EISSN
2167-9223
Publication Date
February 2017
Volume
18
Issue
1-2
Start / End Page
148 / 151
Location
England
Related Subject Headings
- Treatment Outcome
- Serine
- Risk
- Humans
- Clinical Trials as Topic
- Amyotrophic Lateral Sclerosis
- 3209 Neurosciences
- 1109 Neurosciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
ALSUntangled Group. (2017). ALSUntangled 38: L-serine. Amyotroph Lateral Scler Frontotemporal Degener, 18(1–2), 148–151. https://doi.org/10.1080/21678421.2016.1250353
ALSUntangled Group. “ALSUntangled 38: L-serine.” Amyotroph Lateral Scler Frontotemporal Degener 18, no. 1–2 (February 2017): 148–51. https://doi.org/10.1080/21678421.2016.1250353.
ALSUntangled Group. ALSUntangled 38: L-serine. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1–2):148–51.
ALSUntangled Group. “ALSUntangled 38: L-serine.” Amyotroph Lateral Scler Frontotemporal Degener, vol. 18, no. 1–2, Feb. 2017, pp. 148–51. Pubmed, doi:10.1080/21678421.2016.1250353.
ALSUntangled Group. ALSUntangled 38: L-serine. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1–2):148–151.
Published In
Amyotroph Lateral Scler Frontotemporal Degener
DOI
EISSN
2167-9223
Publication Date
February 2017
Volume
18
Issue
1-2
Start / End Page
148 / 151
Location
England
Related Subject Headings
- Treatment Outcome
- Serine
- Risk
- Humans
- Clinical Trials as Topic
- Amyotrophic Lateral Sclerosis
- 3209 Neurosciences
- 1109 Neurosciences
- 1103 Clinical Sciences